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Background. Cessation rates in smokers attending special clinics or their General Practitioners can be 
increased by transdermal nicotine (TNS). This study assesses the efficacy of TNS as an adjunct to advice and 
support in helping patients attending hospital with smoking-related diseases to stop smoking. 
Methods. In a double-blind, placebo-controlled, randomized manner, 234 inpatients and outpatients with 
smoking-related respiratory or cardiovascular disease, aged 1875 years, who were willing to try to stop 
smoking, were advised by their hospital doctor to stop smoking. This was reinforced by repeated advice and 
encouragement from the Smoking Cessation Counsellor initially and at 2, 4, 8 and 12 weeks, supplemented by 
a 24 h patch in adjusted doses over that period. Those not smoking at 12 weeks were followed up at 26 and 
52 weeks. Self-reported complete abstinence from 12 to 52 weeks was validated by expired air carbon 
monoxide measurement at 12, 26 and 52 weeks. 
Results. Twenty-four (21%) of 115 TNS patients were verified as non-smokers at 12,26 and 52 weeks and claimed 
continued abstinence, compared with 17 (14%) of 119 in the placebo (P) group (P=O.15) - 5% confidence 
limits for odds ratio of abstinence on TNS compared to P: 0.83, 3.37. Cessation was related to increasing age 
(P=O.O2) and lower Fagerstrom score (P=O.O5). Minor skin reactions were more frequent in the TNS group 
(47% TNS; 34% P), as was nausea (12% TNS; 3% P). Severe skin reactions were rare (5% TNS; 4% P). 
Conclusion. The suggestion that TNS produces an increase of 50% in relative terms (7% absolute increase) in 
smoking cessation over placebo in this population of hospital patients is sufficiently strong to warrant a 
further study large enough to answer whether or not this result was due to chance. 
Introduction 
Transdermal nicotine (TNS) is effective when used 
in specialized smoking cessation settings (1,2) and in 
general practice when used as an adjunct to support 
and counselling (3,4). For hospital patients with 
smoking-related diseases, moderate levels of advice 
and support, with or without nicotine chewing gum, 
resulted in 20% sustained cessation at 1 yr (5) which 
is much better than the success rates when minimal 
amounts of advice and support were used in similar 
populations (6,7). In outpatients, Foulds et al. (8) 
observed 13.7% abstinence at 12 weeks with TNS 
compared with 10.5”/0 for placebo patches (P=O.15). 
The present study includes inpatients as well as 
outpatients and reports cessation at 1 yr. 
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Patients and Methods 
PATIENTS ELIGIBLE 
Hospital inpatients and outpatients with smoking- 
related respiratory or cardiovascular disease, aged 
18-75 years, who were willing to try to stop smoking. 
They must have smoked 21 cigarette daily within 
1 week prior to admission to hospital or attendance 
at outpatients. 
PATIENTS NOT ELIGIBLE 
Cigar or pipe smokers, those with hypersensitivity 
to any adhesive cutaneous application, any skin 
disease, myocardial infarction within the previous 
month, severe cardiac arrhythmias, pregnancy or 
lactation, patients with mental disturbances and 
patients with terminal or pre-terminal cancer. 
Design and Method 
Patients were advised by their physicians to stop 
smoking. The Smoking Cessation Counsellor (ST-B) 
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Figure I Nicotine vs. placebo patch: initial 12 weeks. SM, smoker; N-SM, non-smoker (no cigarette between two visits, 
except at 12 weeks when no cigarette for previous 48 h); CO, carbon monoxide measurement. 
later asked those patients who fitted the inclusion 
criteria whether they would try to stop smoking. If 
they agreed, these patients were invited to enter the 
trial. Written, informed consent was obtained from 
each participant and the study passed by the local 
Ethics Committee. Patients were stratified according 
to their in/out-patient status and outpatients further 
stratified according to the level of nicotine depend- 
ence as measured by the Fagerstrom score (9). Out- 
patients with a high Fagerstrom Score (3 7) were 
randomized to 40 cm2 nicotine (TNS) or placebo (P) 
patches and those who scored < 6 were prescribed a 
20 cm* TNS or P patch. Inpatients, already abstinent 
by virtue of being in a hospital ward, were ran- 
domized to 20 cm* TNS or P patches regardless of 
their Fagerstrom score. At the first encounter, ST-B 
discussed smoking cessation with each patient, and 
spent 30-60 min doing this, issuing the patches and 
giving instruction on their use. 
DRUGS AND DOSAGE 
The 30 cm* transdermal nicotine patch contained 
52.5 mg nicotine, delivering 21 mg day- ‘. The 
20 cm* transdermal nicotine patch contained 35 mg 
nicotine, delivering 14 mg day- ‘. The 10 cm* 
transdermal nicotine patch contained 17.5 mg nico- 
tine, delivering 7 mg day - i. Patients in the P group 
received a transdermal formulation with a very low 
content of nicotine (13% of the active form), a dose 
which is conventionally felt to be too low to affect 
outcome. 
Treatment lasted 12 weeks during which period all 
patients were asked to return to the Outpatient Clinic 
to see ST-B at 2 weeks, 4 weeks, 8 weeks and 12 
weeks, dosage being altered at each visit according to 
their smoking status (Fig. 1). At each return visit, 
support and encouragement were given to the patient 
and patient compliance estimated by counting used 
and unused patches. A direct question about smok- 
ing status was asked, and those who claimed not to 
have smoked at all between visits were classed non- 
smokers. Dosage was adjusted accordingly in these 
patients. Local and systemic tolerability of the 
patches were assessed by direct questioning. Each 
visit lasted between 15-30 min. At the 12-week visit, 
those who said they had not smoked for the previous 
48 h and whose statement was verified by a reading of 
7 ppm or less on the Bedfont Micro Smokerlyzer 
carbon monoxide meter were given an appointment 
for 3 months later (6 months from trial entry). Those 
claiming continuous abstinence at 6 months and 
whose statements were validated by measurements of 
expired air carbon monoxide were asked to return at 
12 months and the assessment repeated. Patients who 
had been classed as smokers at 12 weeks were not 
followed-up. 
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Table I Results at 3 and 12 months 
Transdermal 
nicotine Placebo P-value 
No. patients 115 119 
Abstinent at 12 weeks 37 (32%) 30 (25%) 0.21* 
Sustained abstinence 3-12 months 24 (21%) 17 (14%) 0.15* 
Nausea 14 (12%) 4 (3%) 0.02t 
Erythema/oedema/itch 54 (47%) 40 (34%) 0.05t 
*Calculated from linear logistic model incorporating treatment group, sex, and 
stratification category. tChi-squared test. 
STATISTICAL ANALYSIS 
The planned sample size for the study was 100 
patients per treatment group. This was based on 80% 
power to detect a statistically significant difference at 
the 5% level, if the absolute difference in cessation 
rate was 20%. 
Comparison of proportions between the two treat- 
ment groups was by the Chi-squared test with Yates’ 
correction for continuity. In order to investigate 
which variables were predictive of successful smoking 
cessation and to adjust for imbalances between treat- 
ment groups after randomization, a multiple linear 
logistic regression was employed. 
Results 
Two hundred and thirty-four patients (54% 
female) entered the study from April to December 
1990, 172 (74%) were outpatients (100 with high 
Fagerstrom score, 72 low) and 62 were inpatients (38 
with high Fagerstrom score, 24 low). Mean age was 
49 years (range 18-75, SD 13.3). Three out of four 
patients had respiratory disease. The mean duration 
of smoking was 3 1 yr (SD 13) in both treatment 
groups and the patients were equally divided among 
those smoking 1-15 cigarettes day- ‘, 16-25 ciga- 
rettes day ~ ‘, and more than 25 cigarettes day- ‘, 
with a slight excess of heavy smokers in the TNS 
group. Eighty-five percent of the TNS patients had 
previously attempted to stop smoking, compared to 
80% in the P group. There were more females in the 
TNS group (58%) than the P group (50%) and 
therefore sex was included in the linear logistic model 
used for analysis. There were no other important 
pre-treatment differences between the groups. The 
sample size was greater than planned because of a 
faster than expected recruitment rate. 
A total of 113 patients (57 TNS, 56P) did not 
complete 12 weeks in the study, 21 (14 TNS, 7P) 
because of adverse events, and 92 (43 TNS, 49P) who 
Table 2 Success rates by stratum and treatment 
Stratum 
Success at 1 year 
n o/o 
1 TNS 4149 8.1 
P 815 1 15.6 
2 TNS 12136 33.3 
P 6136 16.6 
3 TNS 8/30 26.6 
P 3132 9.3 
Test of treatment interactions x2=4.3 
P-value=0.12 
Where Stratum 1, Outpatient/high dependency; Stratum 2, 
Outpatient/low dependency; Stratum 3, Inpatient. TNS, 
transdermal nicotine; P, placebo. 
failed to attend for follow-up by this stage. Thirty- 
seven (32%) patients in the TNS group and 30 
patients (25%) in the P group were confirmed non- 
smokers at the end of 12 weeks (Table 1). By the end 
of 1 yr, 24 (21%) patients in the TNS group and 17 
(14%) patients in the P group said they had not 
smoked throughout the period from week 12 to week 
52 and had expired air carbon monoxide tests 
~7 ppm at 12, 26 and 52 weeks. This difference was 
not significant at the 5% level. There was no statisti- 
cally significant interaction between stratum, 
treatment and outcome (Table 2). 
If the analysis is restricted to those patients who 
used the patches as instructed, or withdrew due to 
adverse events or lack of efficacy, the population 
available falls to 166 patients; 87 TNS and 79P. 
The verified, sustained abstinence rates then become 
22% TNS and 13% P (Logistic regression; P=O.13). 
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Successful cessation (sustained absence from 12-52 
weeks) was significantly related to increasing age 
(P=O.O2) and to lower Fagerstrom score (P=O.O5) 
when a stepwise logistic regression was performed. 
Successful cessation was not related to in- or out- 
patient status, diagnosis, sex, number or length of 
time smoked cigarettes, or to previous attempts to 
stop smoking. 
Although more patients in the TNS group com- 
plained of itch and/or erythema and/or oedema 
(Table l), the frequency of skin reactions severe 
enough to cause treatment to be discontinued was 
similar in both groups (5% TNS cf. 4% P). Nausea 
was reported by 12% TNS vs. 3% P (Table 1). The 
majority of patients who experienced nausea had 
continued to smoke while using the patches (TNS 
12/14; P 3/4). 
Discussion 
Patients who continue to smoke when suffering 
from smoking-related diseases severe enough to war- 
rant referral or admission to hospital must be hard- 
core smokers. Previous studies have demonstrated 
how few of these patients (l&13%) gave up smoking 
in response to doctor’s advice, even when advice was 
supplemented by simple support strategies (6, 7). At 
Llandough Hospital, the 12 months’ success rate for 
advice and support supplemented by either nicotine 
gum or placebo gum was 20% (5). At Sahlgrens 
Hospital in Sweden, more intensive support com- 
bined with nicotine chewing gum improved the 
cessation rate to 29% and was superior to placebo 
(16% cessation) in a group of whom two-thirds were 
patients and the remainder were self-referred smokers 
(10). In the present study, nicotine patches used 
together with support have produced results in the 
same range, with a suggestion of superiority over 
placebo patches (21% cf. 14%, P=O.15). Increasing 
age was again found to be a predictor of success, as 
was a low nicotine dependency score, but male sex 
and cardiovascular disease, predictors in previous 
studies (6,7), were not so in this study. However, a 
trend was present for male sex and cardiovascular 
disease, and the lack of significance may be due to 
inadequate power. 
The results at 12 weeks were twice as good for TNS 
and placebo compared with those of Foulds et al. (8). 
The differences may be related to the natures of the 
populations studied and to the counselling. It would 
be interesting to know the success rates at 1 yr in 
Foulds et al.‘s study, as it would in the study 
by DeBusk et al. (12) which reported 70% cessation 
at 2 months in patients admitted to hospital with 
myocardial infarction. 
The relatively high rates of skin reactions in both 
groups indicate that there is much scope to improve 
the patch constituents in contact with the skin, 
although it is likely that TNS will still be more 
irritant than placebo (3,ll). More of the patients in 
the present study experienced nausea than in the 
other two studies in general practice (3,11), perhaps 
because the present study used higher doses for some 
patients. In contrast to those studies, the patients in 
the present study rarely mentioned sleep disturbance. 
The 50% increase in success rate of TNS relative to 
placebo (7% absolute increase) may or may not have 
been a chance finding. A further study large enough 
to answer this question should be conducted and 
should also, ideally, include a third group receiving 
support and advice without patches. 
Acknowledgements 
We thank Ciba-Geigy Ltd for funding this study 
and for providing Nicotine11 TTS and placebo 
patches. The co-operation of members of staff at 
Llandough Hospital is gratefully acknowledged, as is 











Buchkremer G, Bents H, Minneker E, Opitzk K. Com- 
bination of behavioural smoking cessation therapy with 
transdermal nicotine substitution: long-term effects. In: 
Aoki M, Hisamichi S, Tominaga S, eds. Smoking and 
Health. Amsterdam: Excerpta Medica, 1987, 857-860. 
(International Congress Series No. 780). 
Buchkremer G, Minneker E, Block M. Smoking 
cessation treatment combining transdermal nicotine 
substitution with behavioural therapy. Pharmacopsych 
1991; 24: 96102. 
Russell, MAH, Stapleton JA, Feyerabend C et al. 
Targeting heavy smokers in general practice: 
randomised controlled trial of transdermal nicotine 
patches. BMJ 1993; 306: 1308-1312. 
ICRF General Practice Research Group. Randomised 
trial of nicotine patches in general practice - results at 
one year. BMJ 1994; 308: 14761477. 
Campbell IA, Tjeder-Burton SM, Prescott RJ. Smoking 
cessation in hospital patients given repeated advice plus 
nicotine or placebo chewing gum. Respir Med 1991; 86: 
155-157. 
British Thoracic Society. Comparison of four methods 
of smoking withdrawal in patients with smoking-related 
diseases. BMJ 1983; 286: 595-597. 
British Thoracic Society. Smoking cessation in patients: 
two further studies by the British Thoracic Society. 
Thorax 1990; 45: 8355840. 
Foulds J, Stapleton J, Hayward M et al. Transdermal 
nicotine patches with low intensity support to aid 
Transdermal nicotine plus support in smoking-related diseases 51 
smoking cessation in out-patients department in a 
general hospital: a placebo-controlled trial. Arch Fam 
Med 1993; 2: 417423. 
9. Fagerstrom K. Measuring degree of dependence to 
tobacco smoking with reference to individualisation of 
treatment. Addict Behav 1978; 3: 235-241. 
10. Hjalmarson IAM. Effect of nicotine chewing gum in 
smoking cessation. A randomised placebo controlled 
double-blind study. JAMA 1984; 252: 2835-2838. 
11. ICRF General Practice Research Group. Effectiveness 
of a nicotine patch in helping people stop smoking: 
results of a randomised trial in general practice. BMJ 
1993; 306: 1304-1308. 
12. DeBusk RF, Miller NH, Superko HR et al. A case 
management system for coronary risk factor modifi- 
cation after acute myocardial infarction. Ann Intern 
Med 1994: 120: 721-729. 
